• For Researchers

Harnessing the power of CD3

Revolutionising our understanding of cancer risk using a huge variety of data to advance early detection of the disease – it sounds as ambitious as it is exciting, but is it possible? We caught up with Professor Antonis Antoniou to find out... Revolutionising our understanding of cancer risk using a huge variety of data to advance early detection of the disease – it sounds as ambitious as it is exciting, but is it possible? We caught up with Professor Antonis Antoniou to find out...

30 May 2023

• Health & Medicine
• Science & Technology

Stopping neuropathy – one of chemotherapy’s most challenging side effects

Chemotherapy-induced peripheral neuropathy (CIPN) is caused by cancer treatment, but there's no way to treat it. Our work is changing that. Chemotherapy-induced peripheral neuropathy (CIPN) is caused by cancer treatment, but there's no way to treat it. Our work is changing that.

22 May 2023

• Science & Technology

How MRI add-ons could accelerate the development of new treatments

New research from the ICR is showing us how additional measurements taken by MRI could speed up the development of new drugs that could make chemotherapies more effective New research from the ICR is showing us how additional measurements taken by MRI could speed up the development of new drugs that could make chemotherapies more effective

9 May 2023

• Health & Medicine

How longer waiting times are impacting teens and young adults

Concluding our first Teenager and Young Adult Cancer Awareness Month, we look at how longer waiting times are impacting their mental health. Concluding our first Teenager and Young Adult Cancer Awareness Month, we look at how longer waiting times are impacting their mental health.

27 April 2023

• Science & Technology

From smouldering ash to a gleaming temple for cancer research: The new home of Cancer Research UK's Manchester Institute

Martin McGlown, our head of regional media relations, reflects on the 2017 Cancer Research UK Manchester Institute fire and the new research centre that has been rebuilt in its place. Martin McGlown, our head of regional media relations, reflects on the 2017 Cancer Research UK Manchester Institute fire and the new research centre that has been rebuilt in its place.

26 April 2023

• Health & Medicine

FOCUS4: Learning from a landmark clinical trial

FOCUS4 was a large-scale trial investigating new treatments in people with advanced or metastatic colorectal cancer. Running it may not have been without its challenges, but the learnings it provided us with are invaluable if we're to run trials like it again.  FOCUS4 was a large-scale trial investigating new treatments in people with advanced or metastatic colorectal cancer. Running it may not have been without its challenges, but the learnings it provided us with are invaluable if we're to run trials like it again. 

25 April 2023

• Science & Technology
• Health & Medicine

3 ways we're helping teenagers and young adults with cancer

Teenagers and young adults with cancer have to deal with unique challenges. We're using our expertise to help tackle them. Teenagers and young adults with cancer have to deal with unique challenges. We're using our expertise to help tackle them.

18 April 2023

• Science & Technology

How TRACERx is helping us predict lung cancer’s next move

Researchers based at the Francis Crick Institute have published new results from TRACERx, revealing the secrets of how lung cancer can evolve, spread and resist treatment. Researchers based at the Francis Crick Institute have published new results from TRACERx, revealing the secrets of how lung cancer can evolve, spread and resist treatment.

12 April 2023

• Health & Medicine

Olaparib approved for 800 prostate and breast cancer patients in England

Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England.  Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England. 

11 April 2023

• Charity News

Dame Deborah James’ incredible legacy: The Bowelbabe Fund announces first funded projects

In her final weeks, fuelled by her spirit of ‘rebellious hope’ and passion to help others, Deborah worked to establish the Bowelbabe Fund for Cancer Research UK, to support projects she was passionate about. Today the initial projects to receive funding from the Bowelbabe Fund have been announced. In her final weeks, fuelled by her spirit of ‘rebellious hope’ and passion to help others, Deborah worked to establish the Bowelbabe Fund for Cancer Research UK, to support projects she was passionate about. Today the initial projects to receive funding from the Bowelbabe Fund have been announced.

5 April 2023

• Health & Medicine

Children’s cancer charities team up for tomorrow’s treatments

We're helping treble funding for paediatric Experimental Cancer Medicine Centres, paving the way to more effective and less toxic treatments for children and young people. We're helping treble funding for paediatric Experimental Cancer Medicine Centres, paving the way to more effective and less toxic treatments for children and young people.

3 April 2023

• Health & Medicine
• Science & Technology

Scientists uncover how incurable skin cancer resists treatment at the end of life

New results from the Cancer Research UK-funded PEACE study have revealed how some skin cancers stop responding to treatment at the end of life. New results from the Cancer Research UK-funded PEACE study have revealed how some skin cancers stop responding to treatment at the end of life.

29 March 2023